Printer Friendly

BridgeBio Pharma signs purchase contract with Alexion Pharmaceuticals.

M2 PHARMA-June 13, 2018-BridgeBio Pharma signs purchase contract with Alexion Pharmaceuticals

(C)2018 M2 COMMUNICATIONS

United States-based BridgeBio Pharma has signed a purchase contract with United States-based Alexion Pharmaceuticals.

It was reported yesterday that the contract has been signed to acquire cyclic pyranopterin monophosphate (cPMP; ALXN1101), a synthetic enzyme co-factor therapy for patients with the ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A.

ALXN1101 is a synthetic version of cPMP, the missing cofactor causing MoCD Type A. In earlier work with a recombinant form of cPMP, 11 patients with MoCD Type A had normalisation of biomarkers within two days, eight patients showed some suppression of seizures, and three patients had near-normal development. ALXN1101 has received Breakthrough Therapy designation from the US FDA.

Although the specific terms of the deal have not been disclosed, BridgeBio has committed sufficient resources to Origin Biosciences to enable clinical development, regulatory approval and to support commercialisation of ALXN1101. Alexion will receive additional payments for development and sales milestones.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 13, 2018
Words:176
Previous Article:AstraZeneca and Eli Lilly terminate global phase three clinical trials of lanabecestat.
Next Article:Sanofi Pasteur to acquire Translate Bio's mRNA technology.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |